Teva Completes Denosumab Biosimilar Pair With FDA Nod for Degevma
The FDA has approved denosumab-adet (Degevma; Teva Pharmaceutical Industries), a biosimilar to Xgeva (denosumab; Amgen), across all indications of the reference product, Teva announced September 28, 2026.1 Degevma is indicated to prevent bone complications …